anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 76,021-76,050
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

76,021-76,050 of 110,355

filter-aware
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations 1 hit
08
Includes flow cytometry plots and bar charts showing efficacy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
09
The slide highlights the structural modification of the binding domain in NXC-201 compared to the reference Abecma.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
10
The slide uses a schematic diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
16
The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
17
Includes comparative data points for CAR-T characteristics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
19
The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
27
The slide uses a before-and-after visual comparison to illustrate market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
38
The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
41
Uses icon-based visualization to represent market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a process flow diagram to illustrate dose escalation steps.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
43
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
44
The table highlights specific adverse events (CRS and ICANS) within a red dashed box.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
45
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
46
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit